Has anyone seen this, posted on social media 2 hours ago:
“We all share a common interest in the success of Cytodyn. The following is an excerpt of a positive letter (signatures removed, etc.) that was sent to and received by Cytodyn management and Board of directors by a group of investors who own over 175 Million shares for your review and discussion.
The group is committed to supporting the success of leronlimab and the stock, and is anticipating one or more breakthroughs in the near future.”
Dr. Pourhassen et al,
We are writing you on behalf of CytoDyn shareholders representing over 175,000,000 shares of common stock and growing. The signatures below represent only a portion of the commitment to this position. It is our strong recommendation that CytoDyn reach out to Dr. Bruce Patterson, CEO of IncellDx to reestablish a robust cooperative, collaborative, and harmonious scientific and business relationship. We are all strong supporters of CytoDyn, with a great deal of patience. Please do not underestimate our dedication to what is in the best interest of the shareholders - a goal you and we are aligned on, and a sentiment you have expressed on many occasions.
After exhaustive research (including consultations with scientific, medical, and knowledgeable pharmaceutical investors), it is our belief that CytoDyn’s FDA approval and/or authorization will be greatly enhanced by a collaboration with Dr. Patterson and the IncellDx team.
Covid-19 cases are rising on average by over 170,000 cases per day. Deaths have already risen to between 1,500 and 2,000 daily. This means another 50,000 Americans alone will die before year’s end. It becomes increasingly difficult to see these numbers knowing there is a therapeutic that can alleviate the rising hospitalizations and significantly reduce death. Many investors in CYDY are here for the science. To the people who support CytoDyn for the science and for humanity, the company has an obligation to pursue changes that will maximize our chances of bringing these possibilities to fruition. Dr. Bruce Patterson is the person who can maximize those chances.
We understand that there is a "strained" relationship between CytoDyn and Dr. Patterson. We are business people who have learned that negotiations, rather than disagreements, are required when there is an opportunity to help save lives, while not losing sight of our goals for growth and profit. We’re only interested in what is best for CytoDyn . Therefore, the following is our collective thinking as it relates to Dr. Patterson:
1) Dr. Patterson has published 3 papers (1 each, in each of Leronlimab’s indications) in the last year, with 3 more pending on COVID, which Dr. Patterson has talked about in various seminars. For this very reason he has established overwhelming credibility with the majority of CytoDyn shareholders, along with the entire scientific community.
2) More scientifically inclined members of our group (there are many) have indicated that the HIV paper which Dr. Patterson co-authored could have implications for the mono-therapy trial. An IncellDx investor informed us that IncellDx was NOT involved in the combination therapy trial, and only became involved in the later stages of the mono-therapy trial. Dr. Pourhassen, we are all sophisticated and experienced investors with large positions in this company. You can't deny the fact that the BLA has been delayed to the point in which shareholders are entitled to explicit answers as to why. The re-submitted BLA filing with the FDA for HIV might very well be the most important step the company will ever take. A margin for error no longer exists. We all believe that Dr. Patterson's expertise with this critical step, will help to expedite the filing of an unassailable document.
3) Over 1,000 people listened to Dr. Patterson's webcast on long haulers and heard about the paper to be submitted regarding his study of over 100 such patients. IncellDx has been leading the way in long hauler research and treatment. We have third party opinions that the IncellDx quantitative CCR5 IHC assay with a scoring system that can be followed, is far superior to what is available on the market today for CCR5 IHC.
4) As previously stated, we have very sophisticated and scientifically minded members in our group. They have compared IncellDx’s receptor occupancy assay performed on Leronlimab, Pfizer’s Maraviroc, and Orion’s OB-002, and suggest that IncellDx RO assays are the best on the market because they control for variation in the naturally variable expression levels of CCR5 in COVID, cancer, and HIV. Dr. Patterson discussed this in his clinical OMICS webinar last week. Consequently, we only see upside in working with IncellDx for the benefit of our shareholders, leveraging his knowledge and expertise for the benefit of CytoDyn.
5) IncellDx filed a patent in 2017, on targeting CCR5 on Tregs in cancer, and was the focus of a recent publication. As shareholders, this seems like a tremendous opportunity for growth and value. What would be the downside of joining forces?
6) It is our understanding from a Board member of IncellDx that they filed patents on CCR5 AND RANTES as targets in COVID, independent of any drug. What better way to leverage their IP than to have a joint value proposition in the market.
While not purporting to assure Dr. Patterson’s response to an invitation to meet (virtually), given the complementing strengths of each company, we anticipate that he will recognize the value of discussing how IncellDx and CytoDyn can work together again for the mutual benefit of both parties and their shareholders. Before we do, we need a sign that you are open to a discussion.
Let’s focus on driving shareholder value together. Let us help you to facilitate the first step in the re-engagement process.
Very Truly Yours,
“We all share a common interest in the success of Cytodyn. The following is an excerpt of a positive letter (signatures removed, etc.) that was sent to and received by Cytodyn management and Board of directors by a group of investors who own over 175 Million shares for your review and discussion.
The group is committed to supporting the success of leronlimab and the stock, and is anticipating one or more breakthroughs in the near future.”
Dr. Pourhassen et al,
We are writing you on behalf of CytoDyn shareholders representing over 175,000,000 shares of common stock and growing. The signatures below represent only a portion of the commitment to this position. It is our strong recommendation that CytoDyn reach out to Dr. Bruce Patterson, CEO of IncellDx to reestablish a robust cooperative, collaborative, and harmonious scientific and business relationship. We are all strong supporters of CytoDyn, with a great deal of patience. Please do not underestimate our dedication to what is in the best interest of the shareholders - a goal you and we are aligned on, and a sentiment you have expressed on many occasions.
After exhaustive research (including consultations with scientific, medical, and knowledgeable pharmaceutical investors), it is our belief that CytoDyn’s FDA approval and/or authorization will be greatly enhanced by a collaboration with Dr. Patterson and the IncellDx team.
Covid-19 cases are rising on average by over 170,000 cases per day. Deaths have already risen to between 1,500 and 2,000 daily. This means another 50,000 Americans alone will die before year’s end. It becomes increasingly difficult to see these numbers knowing there is a therapeutic that can alleviate the rising hospitalizations and significantly reduce death. Many investors in CYDY are here for the science. To the people who support CytoDyn for the science and for humanity, the company has an obligation to pursue changes that will maximize our chances of bringing these possibilities to fruition. Dr. Bruce Patterson is the person who can maximize those chances.
We understand that there is a "strained" relationship between CytoDyn and Dr. Patterson. We are business people who have learned that negotiations, rather than disagreements, are required when there is an opportunity to help save lives, while not losing sight of our goals for growth and profit. We’re only interested in what is best for CytoDyn . Therefore, the following is our collective thinking as it relates to Dr. Patterson:
1) Dr. Patterson has published 3 papers (1 each, in each of Leronlimab’s indications) in the last year, with 3 more pending on COVID, which Dr. Patterson has talked about in various seminars. For this very reason he has established overwhelming credibility with the majority of CytoDyn shareholders, along with the entire scientific community.
2) More scientifically inclined members of our group (there are many) have indicated that the HIV paper which Dr. Patterson co-authored could have implications for the mono-therapy trial. An IncellDx investor informed us that IncellDx was NOT involved in the combination therapy trial, and only became involved in the later stages of the mono-therapy trial. Dr. Pourhassen, we are all sophisticated and experienced investors with large positions in this company. You can't deny the fact that the BLA has been delayed to the point in which shareholders are entitled to explicit answers as to why. The re-submitted BLA filing with the FDA for HIV might very well be the most important step the company will ever take. A margin for error no longer exists. We all believe that Dr. Patterson's expertise with this critical step, will help to expedite the filing of an unassailable document.
3) Over 1,000 people listened to Dr. Patterson's webcast on long haulers and heard about the paper to be submitted regarding his study of over 100 such patients. IncellDx has been leading the way in long hauler research and treatment. We have third party opinions that the IncellDx quantitative CCR5 IHC assay with a scoring system that can be followed, is far superior to what is available on the market today for CCR5 IHC.
4) As previously stated, we have very sophisticated and scientifically minded members in our group. They have compared IncellDx’s receptor occupancy assay performed on Leronlimab, Pfizer’s Maraviroc, and Orion’s OB-002, and suggest that IncellDx RO assays are the best on the market because they control for variation in the naturally variable expression levels of CCR5 in COVID, cancer, and HIV. Dr. Patterson discussed this in his clinical OMICS webinar last week. Consequently, we only see upside in working with IncellDx for the benefit of our shareholders, leveraging his knowledge and expertise for the benefit of CytoDyn.
5) IncellDx filed a patent in 2017, on targeting CCR5 on Tregs in cancer, and was the focus of a recent publication. As shareholders, this seems like a tremendous opportunity for growth and value. What would be the downside of joining forces?
6) It is our understanding from a Board member of IncellDx that they filed patents on CCR5 AND RANTES as targets in COVID, independent of any drug. What better way to leverage their IP than to have a joint value proposition in the market.
While not purporting to assure Dr. Patterson’s response to an invitation to meet (virtually), given the complementing strengths of each company, we anticipate that he will recognize the value of discussing how IncellDx and CytoDyn can work together again for the mutual benefit of both parties and their shareholders. Before we do, we need a sign that you are open to a discussion.
Let’s focus on driving shareholder value together. Let us help you to facilitate the first step in the re-engagement process.
Very Truly Yours,
8
4
